Vol 3 (February 25, 2025): AME Clinical Trials Review

Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial

How do we improve chemoimmunotherapy in gastroesophageal adenocarcinoma?

Final survival analysis from the LACC trial defines the current standard of care in surgical treatment of cervical cancer, however does not mark the final say

Targeting menin in relapsed or refractory acute myeloid leukaemia—where the rubber hits the road

Re-evaluating antiplatelet therapy post-coronary artery bypass grafting: insights from the DACAB trial’s five-year follow-up

Innovative dual approach: CD40 agonist and mFOLFIRINOX combination therapy in metastatic pancreatic cancer

DACAB trial supports long-term use of ticagrelor and aspirin dual therapy after coronary artery bypass grafting

Is EndoRotor the answer to residual colonic lesions?

Should we target demethylation in acute myeloid leukemia?

Upfront axillary surgical management—a commentary on previously underrepresented patient groups and how the SENOMAC trial righted this wrong